CAR-T cell expansion platforms yield distinct T cell differentiation states.

Autor: Song HW; Department of Transfusion Medicine, Center for Cellular Engineering, National Institutes of Health, Bethesda, MD, USA., Prochazkova M; Department of Transfusion Medicine, Center for Cellular Engineering, National Institutes of Health, Bethesda, MD, USA., Shao L; Department of Transfusion Medicine, Center for Cellular Engineering, National Institutes of Health, Bethesda, MD, USA., Traynor R; Department of Transfusion Medicine, Center for Cellular Engineering, National Institutes of Health, Bethesda, MD, USA., Underwood S; Department of Transfusion Medicine, Center for Cellular Engineering, National Institutes of Health, Bethesda, MD, USA., Black M; Department of Transfusion Medicine, Center for Cellular Engineering, National Institutes of Health, Bethesda, MD, USA., Fellowes V; Center for Immuno-Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Shi R; Department of Transfusion Medicine, Center for Cellular Engineering, National Institutes of Health, Bethesda, MD, USA., Pouzolles M; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Chou HC; Genomics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Cheuk AT; Genomics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Taylor N; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Jin P; Department of Transfusion Medicine, Center for Cellular Engineering, National Institutes of Health, Bethesda, MD, USA., Somerville RP; Department of Transfusion Medicine, Center for Cellular Engineering, National Institutes of Health, Bethesda, MD, USA., Stroncek DF; Department of Transfusion Medicine, Center for Cellular Engineering, National Institutes of Health, Bethesda, MD, USA., Khan J; Genomics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Highfill SL; Department of Transfusion Medicine, Center for Cellular Engineering, National Institutes of Health, Bethesda, MD, USA. Electronic address: steven.highfill@nih.gov.

Publikováno v: Cytotherapy [Cytotherapy] 2024 Jul; Vol. 26 (7), pp. 757-768. Date of Electronic Publication: 2024 Mar 12.

Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.

Autor: Tian M, Wei JS, Shivaprasad N, Highfill SL, Gryder BE, Milewski D, Brown GT, Moses L, Song H, Wu JT, Azorsa P, Kumar J, Schneider D, Chou HC, Song YK, Rahmy A, Masih KE, Kim YY, Belyea B, Linardic CM, Dropulic B, Sullivan PM, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL, Orentas RJ, Cheuk AT, Khan J

Publikováno v: Cell reports. Medicine [Cell Rep Med] 2024 May 21; Vol. 5 (5), pp. 101586. Date of Electronic Publication: 2024 May 09.

Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.

Autor: Brudno JN; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Natrakul DA; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Karrs J; Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Patel N; Hematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD., Maass-Moreno R; Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD., Ahlman MA; Department of Radiology and Imaging, Medical College of Georgia, Augusta, GA., Mikkilineni L; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Mann J; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Stroncek DF; Center for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD., Highfill SL; Center for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD., Fromm GC; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Patel R; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Pittaluga S; Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Kochenderfer JN; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Publikováno v: Blood advances [Blood Adv] 2024 Feb 13; Vol. 8 (3), pp. 802-814.

Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain.

Autor: Mikkilineni L; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Natrakul DA; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Lam N; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Manasanch EE; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mann J; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Weissler KA; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Wong N; Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research in the CCR Collaborative Bioinformatics Resource, National Cancer Institute, Bethesda, MD, USA., Brudno JN; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Goff SL; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yang JC; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Ganaden M; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Patel R; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zheng Z; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Gartner JJ; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Martin KR; Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA., Wang HW; Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yuan CM; Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Lowe T; Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Maric I; Hematology Service, Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, MD, USA., Shao L; Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA., Jin P; Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA., Stroncek DF; Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA., Highfill SL; Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA., Rosenberg SA; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Kochenderfer JN; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: kochendj@mail.nih.gov.

Publikováno v: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2024 Feb 07; Vol. 32 (2), pp. 503-526. Date of Electronic Publication: 2023 Dec 28.

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.

Autor: Kaczanowska S; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Murty T; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Alimadadi A; La Jolla Institute for Immunology, La Jolla, CA, USA; Immunology Center of Georgia, Augusta University, Augusta, GA, USA; Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA, USA., Contreras CF; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Department of Oncology, University of Oxford, Oxford, UK., Duault C; Stanford Human Immune Monitoring Center, Stanford University School of Medicine, Stanford, CA, USA., Subrahmanyam PB; Stanford Human Immune Monitoring Center, Stanford University School of Medicine, Stanford, CA, USA., Reynolds W; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Gutierrez NA; La Jolla Institute for Immunology, La Jolla, CA, USA., Baskar R; Department of Pathology, Stanford University, Stanford, CA, USA., Wu CJ; Broad Institute, Cambridge, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA., Michor F; Broad Institute, Cambridge, MA, USA., Altreuter J; Broad Institute, Cambridge, MA, USA., Liu Y; Broad Institute, Cambridge, MA, USA., Jhaveri A; Broad Institute, Cambridge, MA, USA., Duong V; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Anbunathan H; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Ong C; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zhang H; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Moravec R; Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yu J; Dana-Farber Cancer Institute, Boston, MA, USA., Biswas R; Dana-Farber Cancer Institute, Boston, MA, USA., Van Nostrand S; Dana-Farber Cancer Institute, Boston, MA, USA., Lindsay J; Dana-Farber Cancer Institute, Boston, MA, USA., Pichavant M; Immunology Center of Georgia, Augusta University, Augusta, GA, USA., Sotillo E; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Bernstein D; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Carbonell A; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Derdak J; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Klicka-Skeels J; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Segal JE; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Dombi E; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Harmon SA; Artificial Intelligence Resource, Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Turkbey B; Artificial Intelligence Resource, Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Sahaf B; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Bendall S; Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA, USA., Maecker H; Immunology Center of Georgia, Augusta University, Augusta, GA, USA., Highfill SL; Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD, USA., Stroncek D; Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD, USA., Glod J; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Merchant M; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Hedrick CC; La Jolla Institute for Immunology, La Jolla, CA, USA; Immunology Center of Georgia, Augusta University, Augusta, GA, USA; Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA, USA., Mackall CL; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Ramakrishna S; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: ramakrs@stanford.edu., Kaplan RN; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: rosie.kaplan@nih.gov.

Publikováno v: Cancer cell [Cancer Cell] 2024 Jan 08; Vol. 42 (1), pp. 35-51.e8. Date of Electronic Publication: 2023 Dec 21.